HIV and antiretroviral therapy in the brain: neuronal injury and repair

  title={HIV and antiretroviral therapy in the brain: neuronal injury and repair},
  author={Ronald J. Ellis and Dianne Langford and Eliezer Masliah},
  journal={Nature Reviews Neuroscience},
Approximately 40 million people worldwide are infected with human immunodeficiency virus (HIV). Despite HIV's known propensity to infect the CNS and cause neurological disease, HIV neurocognitive disorders remain under-recognized. Although combination antiretroviral therapy has improved the health of millions of those living with HIV, the penetration into the CNS of many such therapies is limited, and patients' quality of life continues to be diminished by milder, residual neurocognitive… 

HIV, Antiretroviral Therapies, and the Brain

Recent studies demonstrate that CART regimens with higher central nervous system (CNS) penetration effectiveness ranks may improve neurocognitive functioning, and earlier treatment initiation may be considered to protect the CNS.

Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction

Combination therapies that lower CNS viral load and improve immune homeostasis and neuroprotection will be required to address the neuropathogenesis of HIV infection.

HIV-associated synaptic degeneration

Identifying the specific mechanism of the synaptic degeneration may facilitate the development of effective therapeutic approaches to treat HIV-associated neurocognitive disorders (HAND).

Neurotoxicity of Human Immunodeficiency Virus-1: Viral Proteins and Axonal Transport

New evidence of a direct interaction of the HIV protein gp120 with neurons is described, which might play a role in the etiopathology of HAND.

HIV Neuroinvasion: Early Events, Late Manifestations

This chapter addresses selected aspects of the current understanding of HIV neuropathogenesis, based on in vivo and in vitro studies, which are modulated directly and indirectly through chemokine/chemokine receptor interactions.

HIV-Associated Neurocognitive Disorders

Treatments that can perturb the viral reservoirs and decrease chronic inflammatory response, in addition to continuing cART, may give the clinician additional tools to prevent HAND.

Human immunodeficiency virus‐associated neurocognitive disorders: Mind the gap

This review attempts to answer why there appears to be a therapeutic gap between the salutary effects of antiretroviral regimens and normalization of neurological function, and discusses the animal models that have helped to elucidate these mechanisms.

Synaptic dysfunction in human immunodeficiency virus type‐1‐positive subjects: inflammation or impaired neuronal plasticity?

Experimental evidence is presented that some of the clinical features of HIV‐mediated neurological impairment could result from altered BDNF/TrkB/p75NTR regulation and function.

Pathogenesis of HIV in the Central Nervous System

This review highlights recent investigations of HIV-related CNS injury with emphasis on cART-era neuropathological mechanisms in the context of both US and international settings.

NeuroAIDS: An Evolving Epidemic

Clinical presentations, underlying pathogenesis and treatments of HIV-induced neurological disorders, a burgeoning group of neurological disorders that include opportunistic infections in addition to distinct HIV-associated neurological syndromes, are reviewed.



Mechanisms of Neuroimmunity and Neurodegeneration Associated with HIV-1 Infection and AIDS

Recently uncovered pathologic neuroimmune and degenerative mechanisms contributing to neuronal damage induced by HIV-1 are addressed and experimental and potentially future therapeutic approaches are discussed.

Pathways to neuronal injury and apoptosis in HIV-associated dementia

Human immunodeficiency virus-1 (HIV-1) can induce dementia with alarming occurrence worldwide, but discovery in brain of HIV-1-binding sites (chemokine receptors) provides new insights.

The neuropathogenesis of AIDS

The studies that are being carried out to determine the respective contributions of infection, and monocyte and macrophage activation, to disease progression are discussed.

Neuroprotective therapy for HIV dementia.

All the placebo controlled clinical trials conducted to date with neuromodulatory/neuroprotective therapy in patients with HIV dementia are reviewed and a thorough review of potential new treatments for HIV dementia based on the experimental literature is provided.

Neuroprotective Strategies for HIV‐1‐Associated Neurologic Disease

  • H. Gelbard
  • Biology, Medicine
    Annals of the New York Academy of Sciences
  • 1999
In vitro models are used to identify novel relationships between several HIV-1 neurotoxins that may be critical to inducing disruption of normal neuronal functions and ultimately causing neuronal apoptosis, and to demonstrate that marked upregulation of the pro-apoptotic gene product caspase 3 occurs in neurons in pediatric patients with HIV- 1-associated neurologic disease.

Simian Immunodeficiency Virus: A Model for NeuroAIDS

The profile of the infection and the host response, and the resulting cognitive, motor, and neurophysiological abnormalities in SIV-infected monkeys, recapitulates many aspects of the functional impairments associated with HIV-induced CNS disease in humans.

Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia.

  • A. Nath
  • Biology
    The Journal of infectious diseases
  • 2002
Future therapeutic strategies must target common mechanisms such as oxidative stress and dysregulation of intracellular calcium involved in virotoxin-mediated neurotoxicity involved in HIV infection of the nervous system.

Dendritic injury is a pathological substrate for human immunodeficiency virus—related cognitive disorders

It appears that even milder neurocognitive impairment reflects microneuroanatomical injury to synaptic structures.

Early penetration of the blood‐brain‐barrier by HIV

It is indicated that HIV infects the CNS early in the course of viral infection and prior to the development of HIV-associated neurologic abnormalities.

The neuropathogenesis of HIV‐1 infection

Broad‐based complementary hypotheses regarding HIV neuropathogenesis are provided and the identification and regulation of neurotoxins produced from HIV‐infected macrophages are central to uncovering how HIV mediates CNS disease.